Obesity is frequently associated with the consumption of high carbohydrate/fat diets leading to hyperinsulinemia. We have demonstrated that soy protein (SP) reduces hyperinsulinemia, but it is unclear by which mechanism. Thus, the purpose of the present work was to establish whether SP stimulates insulin secretion to a lower extent and/or reduces insulin resistance, and to understand its molecular mechanism of action in pancreatic islets of rats with diet-induced obesity. Long-term consumption of SP in a high fat (HF) diet significantly decreased serum glucose, free fatty acids, leptin, and the insulin:glucagon ratio compared with animals fed a casein HF diet. Hyperglycemic clamps indicated that SP stimulated insulin secretion to a lower extent despite HF consumption. Furthermore, there was lower pancreatic islet area and insulin, SREBP-1, PPAR␥, and GLUT-2 mRNA abundance in comparison with rats fed the casein HF diet. Euglycemic-hyperinsulinemic clamps showed that the SP diet prevented insulin resistance despite consumption of a HF diet. Incubation of pancreatic islets with isoflavones reduced insulin secretion and expression of PPAR␥. Addition of amino acids resembling the plasma concentration of rats fed casein stimulated insulin secretion; a response that was reduced by the presence of isoflavones, whereas the amino acid pattern resembling the plasma concentration of rats fed SP barely stimulated insulin release. Infusion of isoflavones during the hyperglycemic clamps did not stimulate insulin secretion. Therefore, isoflavones as well as the amino acid pattern seen after SP consumption stimulated insulin secretion to a lower extent, decreasing PPAR␥, GLUT-2, and SREBP-1 expression, and ameliorating hyperinsulinemia observed during obesity.Obesity is a major health problem around the world because of chronic overnutrition and increase in the sedentary life style (1, 2). The development of obesity is accompanied by several metabolic changes including insulin resistance, hyperinsulinemia, dyslipidemia, hyperleptinemia, and hepatic steatosis among others, known as the metabolic syndrome (3, 4). Thus, the search for therapies to prevent the development of metabolic syndrome has increased over the last few years, including pharmacological and dietary therapies (5-11).Previous studies have shown that long term consumption of soy protein diet reduces hyperinsulinemia, which in turn decreases the expression of the sterol regulatory element-binding protein (SREBP) 2 -1c in liver, reducing hepatic steatosis (12). Furthermore, recent evidence showed that soy protein is able to reduce hepatic lipotoxicity even in the presence of hyperinsulinemia and hyperleptinemia by a reduction in the expression of lipogenic genes and an increase in oxidative pathways (13). This evidence suggests that the type of dietary protein may play an important role in preventing the development of the metabolic syndrome.It is not clear whether the effect of consumption of soy protein on serum insulin concentration is associated with changes in...